Medicinal Market Access & Specialized Med-Tech Commercialization

Overcoming Regulatory Barriers to Deliver Life-Saving Therapeutics to the Middle East and Levant.

Review Serialization Protocols Contact Us!

Bridging the Clinical Supply Vacuum in the GCC and Levant

Entering the Middle Eastern healthcare market is a highly lucrative expansion, yet achieving compliant Clinical Market Access Middle East pathways requires navigating distinct, dual-track regulatory barriers:

The GCC Mandate

Hyper-complex track-and-trace serialization (Tatmeen/RSD).
Intensive domestic localization and compliance policies.

The Levant Vacuum

Critical supply disruptions and regional logistics bottlenecks.
Strict international sanction frameworks and compliance layers.

The § 52c AMG Compliance Shield

Operating strictly under Section 52c of the German Medicinal Products Act, our asset-light mediation completely neutralizes cross-border product liability:

Zero Legal Title Risk: LGP never takes legal ownership or physical possession of the cargo.

Direct Factory-to-Hospital Routing: Sensitive cold-chain biologics and Med-Tech ship directly from the audited European manufacturer to regional Ministries of Health.

Absolute Integrity: Guarantees 100% temperature control, verified pricing transparency, and bulletproof supply chain security.

The Serialization Solution: Tatmeen \& RSD Readiness

KSA: RSD (Rased) Alignment

The Regulatory Friction:
Absolute SFDA enforcement of GS1 DataMatrix (2D) and Serial Shipping Container Code (SSCC) verification. Mismatches mean instant port rejection.

The LGP Compliance Shield:
Factory-Level Audit: Technical validation of physical pallet printing parameters executed on-site prior to shipping manifests locking.

SFDA Hub Verification: Live pre-clearance simulations run directly against the Saudi tracking registries.

Tarmac Insulation: Actively shields high-value clinical standard generics and diagnostics from catastrophic customs delays.

UAE: Tatmeen Integration

The Regulatory Friction:
Mandatory real-time digital aggregation. Minor formatting syntax errors between physical freight and digital portals trigger immediate port-of-entry customs quarantine.

The LGP Compliance Shield:
ERP Synchronization: We map and translate European factory-floor ERP data to match UAE national hub syntax before freight dispatch.

Asset-Light Brokerage: Total administrative pre-clearance under § 52c AMG broker compliance with zero legal title risk.

Frictionless Entry: Converts complex, high-anxiety data logistics into a clear, predictable commercial corridor.

Specialized Clinical Portfolios & Capabilities

Compliant Pharma Sourcing & Cross-Border Technical Mediation

Cold-Chain Biologics & Niche Care
Medical Device Sourcing & Localization
Humanitarian & Sanctions-Compliant Shield

Cold-Chain Biologics

Operational Focus Line: Mediating uninterrupted pipelines for temperature-critical, life-saving therapeutics.

Certification Auditing: Meticulous pre-screening to ensure all mediated technical assets fully comply with current EU MDR Middle East mandates (Regulation EU 2017/745), completely filtering out legacy MDD vulnerabilities.
Dossier Legalization: Complete technical management of Free Sales Certificates (FSC) and ISO 13485 documentation via German competent health authorities and target embassies in Berlin.
Bilingual Adaptation: Assisting Western engineering firms in formatting and localizing clinical evaluation reports and Instructions for Use (IFU) to meet mandatory Arabic/English public health guidelines.

Direct hospital outfitting, diagnostic facility scaling, and clinic procurement across Saudi Arabia, the UAE, and modernizing GCC therapeutic infrastructure networks.

We act as your specialized regulatory liaison, connecting European Med-Tech innovators directly with regional health ministries and authorized local representatives seamlessly.

EU MDR Med-Tech

Operational Focus Line: Navigating European quality metrics to capture high-value Gulf hospital tenders.

Therapeutic Specialization: Brokering direct supply infrastructure for cold-chain Biologicals, critical insulin portfolios, and essential oncology generics.
Supply Shortage Verification: Every inquiry is rigorously cross-checked against the BfArM Lieferengpass register to guarantee exports never compromise domestic EU supply protections.
Consignee Validation: We comprehensively pre-audit the logistical, cold-chain, and storage capacities of regional distributors before facilitating manufacturer contracts.

Solving acute clinical deficits across import-reliant markets (Qatar, Oman, Kuwait) and deep rehabilitation zones requiring stable cold-chain biologics Iraq and Levant corridors.

Under strict § 52c AMG protocols, LGP secures uncompromised product efficacy straight from the European factory floor to regional endpoints, executing zero-liability, asset-light mediation.

Humanitarian Shield

Operational Focus Line: Engineering absolute legal immunity for critical healthcare supply into disrupted markets.

International Law Navigation: Specialized mediation operating strictly within the lawful frameworks of European Union Common Foreign and Security Policy (EU CFSP) sanctions and OFAC parameters.
End-User Authentication: Execution of rigorous, multi-tiered verification of physical, stamped End-User Certificates (EUC) from verified hospital directors and institutional health authorities.
Chemical Pre-Clearance:Meticulous analysis of raw chemical materials under EU Regulation 2021/821 to ensure complete compliance regarding dual-use precursor legislation.

Meticulously structured, ethically protected institutional pharma supply Levant infrastructure, focusing primarily on highly restricted humanitarian support inside Syria and Iraq.

LGP builds an unassailable paper trail for German principals, granting manufacturers total legal confidence to supply high-stakes markets safely and ethically.

Frequently Asked Questions on Clinical Market Access

Product registration in the GCC requires meticulous dossier preparation. We assist European manufacturers in formatting their clinical data, stability studies, and pricing certificates to align with the specific eCTD (Electronic Common Technical Document) requirements of the Saudi SFDA, UAE MoHAP, and other regional authorities. We act as the technical liaison between the manufacturer and the local authorized representative.

As a § 52c AMG mediator, LGP does not operate physical warehouses or logistics fleets. We broker the direct contract between the European manufacturer and the Middle Eastern buyer. However, as part of our Quality Assurance protocol, we rigorously audit the designated freight forwarders and regional distributors to ensure they hold valid Good Distribution Practice (GDP) certifications necessary for handling cold-chain biologics.

To maintain the absolute integrity of our compliance shield and eliminate any conflict of interest with primary research ecosystems, LGP enforces a strict, voluntary Therapeutic Negative List. We categorically refuse the mediation of narcotics (BtM), psychoactive substances, unverified nutritional supplements, and aesthetic products. Furthermore, we exclude highly innovative, patented portfolios in Respiratory (LAMA/LABA/ICS) and Cardiometabolism (SGLT2 inhibitors/NOACs). Our resources are dedicated 100% to essential standard generics, vital life-saving therapeutics, and validated medical technology.

Secure Your Technical Consultation

Use the form below to outline your product portfolio (Standard Generics, Biosimilars, or Med-Tech hardware), and our lead consultant will contact your regulatory team within 24 business hours.